Propanc Biopharma’s Joint Research Partner Pushing Boundaries to Circumvent Chemotherapy Resistance Using PRP
Research by this team of scientists, led by Professor Elisa Giovanetti, focuses on chemotherapy resistance in pancreatic cancer.
- Research by this team of scientists, led by Professor Elisa Giovanetti, focuses on chemotherapy resistance in pancreatic cancer.
- “Chemotherapy is still considered an irreplaceable front-line therapeutic strategy to treat cancer.
- But multidrug resistance represents a common hurdle that profoundly compromises clinical outcomes, especially in pancreatic cancer.
- Tumor resistance to frontline chemotherapy means a poor prognosis for survival, especially in pancreatic cancer.